Two-Month Study of Pig Kidney Xenotransplantation Gives New Hope to the Future of the Organ Supply

NYU Langone Health Pig Kidney Xenotransplant

After 61 days of observation, NYU Langone Health doctors this month completed the longest-documented case of a genetically engineered pig kidney functioning in a human body.

The procedure, known as a xenotransplant, which involves the transplant of an animal organ into a human, was performed on July 14, 2023, and led by Robert Montgomery, MD, DPhil, the H. Leon Pachter, MD, Professor and chair of the Department of Surgery and director of the NYU Langone Transplant Institute. The organ was removed September 13, 2023, from a 58-year-old man who had been on a ventilator, with his family’s consent, after being declared dead by neurologic criteria before the xenotransplant.

“We have learned a great deal throughout these past two months of close observation and analysis, and there is great reason to be hopeful for the future,” said Dr. Montgomery. “None of this would have been possible without the incredible support we received from the family of our deceased recipient. Thanks to them, we have been able to gain critical insight into xenotransplantation as a hopeful solution to the national organ shortage.”

The study was concluded after reaching its predetermined end date, with the decedent removed from the ventilator and his body returned to the family, as per their wishes.

The procedure was the fifth xenotransplant performed by the Transplant Institute since Dr. Montgomery performed the world’s first genetically modified pig kidney transplant into a human on September 25, 2021. That was followed by a second similar procedure on November 22, 2021. Surgeons at NYU Langone then performed two genetically engineered pig heart transplants in summer 2022.

The kidney used in this procedure was procured from what is known as a GalSafe pig, an animal engineered by Revivicor Inc., a subsidiary of United Therapeutics Corporation. In December 2020, the U.S. Food and Drug Administration (FDA) approved the GalSafe pig as a potential source for human therapeutics, as well as a food source for people with alpha-gal syndrome, a meat allergy caused by a tick bite.

By “knocking out” the single gene that encodes the biomolecule known as alpha-gal—which has been identified as responsible for a rapid antibody-mediated rejection of pig organs by humans—immediate rejection has been avoided in all five xenotransplants at NYU Langone. Additionally, the pig’s thymus gland, which is responsible for educating the immune system, was fused with the pig kidney to stave off novel, delayed immune responses.

While previous genetically engineered pig organ transplants have incorporated up to 10 genetic modifications, this latest study shows that a single-gene knockout pig kidney can perform optimally after two months.

Author

+ posts

Leave a Reply

Your email address will not be published. Required fields are marked *